GLP-1 use during early pregnancy may not increase risk of major adverse outcomes Taking GLP-1s during the first trimester of pregnancy does not appear to substantially increase the risk of adverse outcomes, according to a new study led by Harvard T.H
Food & Drug Administration, 2023 Source: Hall et al., Endocrinology Today, 2022 Trinity-X is a research-grade peptide known for its tri-agonist activity activating GLP-1, GIP, and glucagon receptors simultaneously
Hunger is present but manageable if habits are strong
While many fear unknown side effects, the research highlights specific areas of concern and areas where the peptides are surprisingly safe
Ask a qualified clinician about personal health questions
There is a coincident dehydration of the proteins and of the lens itself